...
首页> 外文期刊>Medicinal chemistry >Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry
【24h】

Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry

机译:用于治疗2型糖尿病的SGLT2抑制剂的设计:生物学到化学的发展史

获取原文
获取原文并翻译 | 示例
           

摘要

A brief history of the design of sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors is reviewed. The design of O-glucoside SGLT2 inhibitors by structural modification of phlorizin, a naturally occurring O-glucoside, in the early stage was a process mainly driven by biology with anticipation of improving SGLT2/SGLT1 selectivity and increasing metabolic stability. Discovery of dapagliflozin, a pioneering C-glucoside SGLT2 inhibitor developed by Bristol-Myers Squibb, represents an important milestone in this history. In the second stage, the design of C-glycoside SGLT2 inhibitors by modifications of the aglycone and glucose moiety of dapagliflozin, an original structural template for almost all C-glycoside SGLT2 inhibitors, was mainly driven by synthetic organic chemistry due to the challenge of designing dapagliflozin derivatives that are patentable, biologically active and synthetically accessible. Structure-activity relationships (SAR) of the SGLT2 inhibitors are also discussed.
机译:回顾了钠依赖性葡萄糖共转运蛋白2(SGLT2)抑制剂设计的简要历史。在早期阶段,通过对自然存在的O-葡萄糖苷phlorizin进行结构修饰来设计O-葡萄糖苷SGLT2抑制剂是一个主要由生物学驱动的过程,期望改善SGLT2 / SGLT1的选择性并提高代谢稳定性。百时美施贵宝(Bristol-Myers Squibb)开发的dapagliflozin是一种开创性的C-葡萄糖苷SGLT2抑制剂,这是该历史上的重要里程碑。在第二阶段,通过修饰dapagliflozin的糖苷配基和葡萄糖部分(几乎是所有C-糖苷SGLT2抑制剂的原始结构模板)来设计C-糖苷SGLT2抑制剂,主要是由于设计的挑战,由合成有机化学驱动达格列净衍生物具有专利性,生物活性且可合成获得。还讨论了SGLT2抑制剂的构效关系(SAR)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号